Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study

Summary: Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes that are important in low-income and middle-income countries. Vaccine effectiveness estimates are scarce in these settings. South Africa replaced PCV7 with PCV13 in 2011 using...

Full description

Bibliographic Details
Main Authors: Cheryl Cohen, DrPhD, Claire von Mollendorf, MD, Linda de Gouveia, NDMedTech, Sarona Lengana, MD, Susan Meiring, MD, Vanessa Quan, MD, Arthermon Nguweneza, MSc, David P Moore, MD, Gary Reubenson, MD, Mamokgethi Moshe, MD, Shabir A Madhi, ProfPhD, Brian Eley, ProfMD, Ute Hallbauer, MD, Heather Finlayson, MD, Sheeba Varughese, MD, Katherine L O'Brien, ProfMD, Elizabeth R Zell, MSc, Keith P Klugman, ProfPhD, Cynthia G Whitney, MD, Anne von Gottberg, PhD
Format: Article
Language:English
Published: Elsevier 2017-03-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X17300438

Internet

http://www.sciencedirect.com/science/article/pii/S2214109X17300438

Similar Items